Background {#s1}
==========

Urolithiasis, also known as urinary calculi disease, develops when a solid piece of material exists in the urinary tract ([@B12]). Most kidney stones form because of a combination of genetics and environmental factors ([@B12]). Urolithiasis have serious consequences if not treated immediately. Cystine urolithiasis (CU) is a genetic disorder characterized by defective renal reabsorption of cystine, arginine, lysine, and ornithine; the increased urinary excretion of cystine results in the formation of kidney stones ([@B6]; [@B7]). Two genes responsible for cystinuria and CU have been identified: *SLC3A1*, which encodes the heavy subunit rBAT of the renal b0,+ transporter; and *SLC7A9*, which encodes b0,+AT, the interacting light subunit of the b0,+ transporter ([@B3]; [@B8]). b0,+ and b0,+AT combine with each other through disulfide linkage, and only the combined b0,+--b0,+AT heterodimer is functional ([@B4]). The inheritance for cystinuria may vary from autosomal recessive (AR) to autosomal dominant (AD) with incomplete penetrance to digenic pattern ([@B5]; [@B14]). Accordingly, cystinuria is divided into the following subtypes: biallelic *SLC3A1* mutations (AA genotype), biallelic *SLC7A9* mutations (BB genotype), a single heterozygous *SLC3A1* mutation (A genotype), a single heterozygous *SLC7A9* mutation (B genotype), and a single heterozygous *SLC3A1* mutation combined with a single heterozygous *SLC7A9* mutation (AB genotype) ([@B5]; [@B14]).

Cystinuria is a global disease with a population-specific prevalence ([@B6]). Although the overall frequency is estimated at 1:7,000 in neonates ([@B16]), the frequency varies in different areas. The rate of CU is 1:2,500 in Libyan Jews, 1:15,000 in Americans, and 1:100,000 in Swedes ([@B18]; [@B16]). In Libyan Jews, the mutant gene carrier rate is as high as 1:25 ([@B18]). In Sweden, 0.5% of the general population carries the *SLC3A1* p.Met467Thr variant ([@B9]; [@B10]). In Asia, cystinuria is rarely reported and its frequency in the Chinese population is unclear.

In this study, we analyzed the composition of 232 samples of kidney stones and subjected 13 cases of childhood CU to genetic analysis. A total of 24 pathogenic variants in *SLC3A1* and *SLC7A9* were detected, 15 of which were novel. These data expanded the spectrum of CU variants in the Chinese population.

Methods {#s2}
=======

Criteria for Pediatric CU and the Controls {#s2_1}
------------------------------------------

Data from pediatric CU patients were collected from 2012 to 2017. A total of 13 CU patients were enrolled in this study ([**Supplementary Data 1**](#SM1){ref-type="supplementary-material"}). Patients were diagnosed with pediatric CU if (i) they were aged 0--18 years old, (ii) passed visible urinary stones under a clinical setting, and (iii) passed pure or cystine stones as identified *via* stone composition analysis. The 26 controls were taken from sporadic cases of patients with calcium oxalate dihydrate stones ([**Supplementary Data 1**](#SM1){ref-type="supplementary-material"}).

DNA Isolation and Sanger Sequencing {#s2_2}
-----------------------------------

Peripheral blood samples were obtained from 13 Trios-families and 26 sporadic cases of other kidney stones (calcium oxalate dihydrate stones). DNA was extracted using a genomic DNA isolation kit (D3392-02; Omega Bio-Tek, Inc., Norcross, GA, USA) in accordance with a standard protocol. The coding regions and intron--exon junctions of the *SLC3A1* and *SLC7A9* genes were amplified *via* PCR by using primers synthesized by BGI, a local biotech company (Shenzhen, China). Primers were designed with Primer3 software (<http://frodo.wi.mit.edu>). The primer sequences and PCR conditions are provided in [**Supplementary Table 1**](#SM2){ref-type="supplementary-material"}. Sanger sequencing was performed on an Applied Biosystems™ 3500 Dx Genetic Analyzer by using a BigDye 3.1 sequencing kit (Applied Biosystems, CA, USA).

Variant Validation {#s2_3}
------------------

All Sanger sequencing results were compared with the reference *SLC3A1* and *SLC7A9* sequences (NM_000341 and NM_014270, GRCh37/hg19, <http://genome.ucsc.edu/cgi-bin/hgGateway>) by applying SEQMAN software (DNA Star Package, Wisconsin, USA). Genetic variants were functionally annotated using InterVar (version 20180118) and screened for reported mutations by using ClinVar (version 20180603) and the HGMD database (public version). We further customized the clinical classification of each variant in accordance with the ACMG/AMP 2015 guidelines by applying automatically interpreted InterVar results and by integrating individualized information, such as family history and inheritance mode, obtained in this study with the results of previous studies.

Results {#s3}
=======

Clinical Data of 13 Patients With Pediatric CU {#s3_1}
----------------------------------------------

A total of 13 patients with CU were identified, 10 of whom were males and 3 were females. These patients originated from 232 patients with urinary stones that we treated from 2002 to 2007. The patients had a mean age of 3.82 ± 3.12 years (range: 0.6--9.3) at first stone onset. The mean stone size of the patient group was 4.12 ± 4.96 cm^3^ (range: 0.26--18.67). Two urethral (3.77%), 2 bladder (3.77%), 14 ureteral (26.42%), 22 renal pelvic or upper/middle calyceal (41.51%), and 13 lower calyceal (46.43%) calculi were noted. Five children had bilateral calculi, whereas two children had staghorn calculi. Seven children had a family history of CU. Twelve patients had normal initial renal function (serum creatinine \[CREA\] 20--120 μmol/L, blood urea nitrogen \[BUN\] 1.8--8.2 mmol/L, and serum uric acid \[UA\] 90--350 μmol/L). The remaining patient with bilateral ureteral calculi exhibited various degrees of renal dysfunction (625.3, 36.82, and 618.8 μmol/L). The mean number of operations was 3.61 ± 2.14 (range: 1--9), including 11 minimally invasive percutaneous nephrolithotomy, 10 retrograde intrarenal surgery, and 26 ureteroscopic lithotripsy. The mean stone-free rate was 46.15% after the final operation. [**Table 1**](#T1){ref-type="table"} lists the clinical features of the 13 patients with CU.

###### 

Clinical features of 13 patients with cystine urolithiasis.

  Characteristics                  Patient 1           Patient 2                            Patient 3     Patient 4                                          Patient 5                            Patient 6      Patient 7      Patient 8               Patient 9   Patient 10                                  Patient 11   Patient 12       Patient 13
  -------------------------------- ------------------- ------------------------------------ ------------- -------------------------------------------------- ------------------------------------ -------------- -------------- ----------------------- ----------- ------------------------------------------- ------------ ---------------- -------------------------------------------
  Gender                           Male                Male                                 Male          Male                                               Female                               Male           Male           Female                  Male        Male                                        Male         Male             Female
  Age, yr                          9.3                 1.7                                  1.8           1                                                  3.1                                  2.8            1.5            8.3                     9.3         2.9                                         0.6          2.8              4.6
  Initial presentation             Stone               Stone                                UTI           GHU                                                Stone                                Stone          Stone          GHU                     Stone       Stone                                       Stone        Stone            GHU
  Bilateral stones                 \-                  \+                                   \+            \-                                                 \-                                   \-             \-             \-                      \-          \+                                          \+           \+               \-
  Staghorn stone                   \+                  \-                                   \-            \-                                                 \-                                   \-             \-             \-                      \-          \+                                          \-           \-               \-
  Number of stones                 6                   2                                    3             4                                                  2                                    2              1              3                       2           14                                          9            2                3
  Stone size(cm^3^)                7.75                2.83                                 2.50          1.18                                               1.28                                 3.41           7.77           0.26                    3.10        18.67                                       1.17         2.51             1.17
  Number of operations             3                   6                                    1             2                                                  3                                    3              1              3                       9           5                                           3            4                4
  MPCNL                            2                   3                                    0             0                                                  0                                    0              0              2                       0           4                                           0            0                0
  RIRS                             1                   0                                    0             1                                                  1                                    1              0              1                       3           0                                           0            0                2
  URL                              0                   3                                    1             1                                                  2                                    2              1              0                       6           1                                           3            4                2
  Family history                   \-                  +(Uncle)                             \-            +(Parents)                                         \-                                   \+ (Brother)   \+ (Brother)   +(Great grand-father)   +(Father)   \-                                          \-           +(Great-uncle)   \-
  Urolithiasis at last follow-up   \-                  \-                                   \+            \+                                                 \-                                   \+             \-             \+                      \+          \+                                          \-           \-               \+
  Infant feeding                   Sanlu milk powder   Breast milk supplemented with milk   Breast milk   Breast milk for 2 months,goat\'s milk thereafter   Breast milk supplemented with milk   Milk powder    Breast milk    Breast milk             Milk        Breast milk for 3 months, milk thereafter   Milk         Breast milk      Breast milk for 3 months, milk thereafter
  Comorbidity                      \-                  \-                                   \-            \-                                                 \-                                   \-             \-             \-                      \-          \-                                          \-           \-               \-
  Serum calcium                    2.3                 2.36                                 2.29          2.51                                               2.35                                 2.38           2.21           2.35                    2.41        2.24                                        2.24         2.19             2.33

Sanlu milk powder was found to contain high levels of melamine. GHU, gross hematuria; MPCNL, minimally invasive percutaneous nephrolithotomy; RIRS, retrograde intrarenal surgery; URL, ureteroscopic lithotripsy.

Identification of *SLC3A1* and *SLC7A9* Variants on 24 Alleles *via* Sanger Sequencing {#s3_2}
--------------------------------------------------------------------------------------

Sanger sequencing was successfully conducted for the 13 patients with pediatric CU and their parents. After filtering out variants with MAF \> 0.01 using the gnomAD database and the variants present in 26 controls, we detected 14 *SLC3A1* and 8 *SLC7A9* variants on 24 alleles from these 13 families ([**Table 2**](#T2){ref-type="table"}, [**Figures 1**](#f1){ref-type="fig"}--[**3**](#f3){ref-type="fig"}). These variants covered the whole spectrum of mutations and ranged from insertion, deletion, splicing, and missense variants. Six families presented with biallelic *SLC3A1* variants (AA genotype) ([**Figure 1**](#f1){ref-type="fig"}), and four families exhibited biallelic *SLC7A9* variants (BB genotype) ([**Figure 2**](#f2){ref-type="fig"}). The genotypes of the remaining three families included a single heterozygous *SLC3A1* variant (A genotype), a single heterozygous *SLC7A9* variant (B genotype), and a single heterozygous *SLC3A1* variant combined with a single heterozygous *SLC7A9* variant (AB genotype) ([**Figure 3**](#f3){ref-type="fig"}).

###### 

Rare variants on *SLC3A1* AND *SLC7A9* detected in 13 families with cystine urolithiasis.

  Patient   Position   Ref   Alt   Gene     Func.refGene                  Exonic Func.             AA Change                         HGMD                                          ACMG interpretation
  --------- ---------- ----- ----- -------- -------------- -------------- ------------------------ --------------------------------- --------------------------------------------- ---------------------------------------------------------------
  1         44528214   C     T     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon6:c.1084C \> T:p.Arg362Cys    Pathogenic, ID : CM961306                     Pathogenic (PS1,PM1,PM2,PM3,PP3,PP4)
  1         44547731   C     T     SLC3A1   exonic         NM_000341      stopgain                 exon10:c.2011C \> T:p.Arg671Ter   NA                                            Pathogenic (PVS1,PM2,PM3,PP3,PP4)
  2         44531471   C     G     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon7:c.1326C \> G:p.Asn442Lys    NA                                            Likely pathogenic (PM2,PM3,PP4)
  2         44547360   C     T     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon10:c.1640C \> T:p.Ser547Leu   Pathogenic, ID : CM014096,CM034062,CM070067   Pathogenic (PS1,PM1,PM2,PM3,PP3,PP4)
  3         33353446   G     --    SLC7A9   exonic         NM_001126335   stopgain                 exon5:c.525delC:p.Tyr175Ter       NA                                            Pathogenic (PVS1,PM2,PP3,PP4)
  3         33324050   C     G     SLC7A9   intronic       NM_001126335   splicing                 Intron12:c.1399+5C \> G           NA                                            Likely pathogenic (PM2,PM3,PP3,PP4)
  4         44531449   T     G     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon7:c.1304T \> G:p.Met435Arg    NA                                            Likely pathogenic (PM1,PM2,PM3,PP3,PP4)
  4         44539806   C     T     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon8:c.1414C \> T:p.Leu472Phe    Pathogenic, ID: HM070022                      Pathogenic (PS1,PM1,PM2,PM3,PP3,PP4)
  5         44528243   C     A     SLC3A1   exonic         NM_000341      stopgain                 exon6:c.1113C \> A:p.Tyr371Ter    NA                                            Pathogenic (PVS1,PM2,PM3,PP4)
  5         44539757   G     --    SLC3A1   exonic         NM_000341      frameshift deletion      exon8:c.1365delG:p.Ser455fs       NA                                            Pathogenic (PVS1,PM2,PM3,PP4)
  6         44528214   C     G     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon6:c.1084C \> G:p.Arg362Gly    Pathogenic, ID: CM961306                      Pathogenic (PS1,PM1,PM2,PP3,PP4)
  6         33353431   GAA   --    SLC7A9   exonic         NM_014270      nonframeshift deletion   c.538_540del:p.Phe180del          NA                                            Likely pathogenic (PM2,PM3,PM4,PP4)
  7         33355244   C     A     SLC7A9   exonic         NM_014270      nonsynonymous SNV        exon4:c.236G \> T:p.Gly79Val      NA                                            Uncertain significance (PM2,PP3,PP4)
  7         33350853   A     G     SLC7A9   exonic         NM_014270      nonsynonymous SNV        exon8:c.767T \> C:p.Ile256Thr     NA                                            Uncertain significance (PM2,PP3,PP4)
  8         33355244   C     A     SLC7A9   exonic         NM_014270      nonsynonymous SNV        exon4:c.236G \> T:p.Gly79Val      NA                                            Uncertain significance (PM2,PP3,PP4)
  8         33350853   A     G     SLC7A9   exonic         NM_014270      nonsynonymous SNV        exon8:c.767T \> C:p.Ile256Thr     NA                                            Uncertain significance (PM2,PP3,PP4)
  9         44513222   T     C     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon4:c.817T \> C:p.Cys273Arg     NA                                            Likely Pathogenic (PM1,PM2,PM3,PP3,PP4)
  9         44528227   A     G     SLC3A1   exonic         NM_000341      nonsynonymous SNV        exon6:c.1097A \> G:p.Gln366Arg    NA                                            Likely Pathogenic (PM1,PM2,PM3,PP3,PP4)
  10        44527229   G     A     SLC3A1   exonic         NM_000341      splicing                 exon5:c.1012-1G \> A              Pathogenic, ID: CS983898                      Pathogenic (PS1,PM2,PP3,PP4)
  11        33324053   --    A     SLC7A9   splicing       NM_014270      splicing                 intron12:c.1399+2_3insT           Pathogenic, ID: CI060712)                     Pathogenic (PVS1,PM2,PP4) \| Uncertain significance (PM2,PP4)
  12        33355619   A     G     SLC7A9   exonic         NM_014270      nonsynonymous SNV        exon3:c.151T \> C:p.Ser51Pro      Pathogenic, ID: CD050153)                     Pathogenic (PS1,PM2,PM3,PP3,PP4)
  12        33333097   T     A     SLC7A9   exonic         NM_014270      stopgain                 exon11:c.1201A \> T:p.Lys401Ter   Pathogenic,p.Lys401Glu, ID: HM070035)         Pathogenic (PVS1,PS1,PM2,PM3,PP3,PP4)
  13        44531479   T     A     SLC3A1   splicing       NM_000341      splicing                 Intron7:c.1332+2T \> A            NA                                            Pathogenic (PVS1,PM2,PM3,PP3,PP4)
  13        44547731   C     T     SLC3A1   exonic         NM_000341      stopgain                 exon10:c.2011C \> T:p.Arg671Ter   NA                                            Pathogenic (PVS1,PM2,PM3,PP3,PP4)

![Rare variants of AA genotypes on six cystine urolithiasis (CU) families. Solid squares or circles mean the patients were affected by CU. Open squares or circles denote that the patients were not affected by CU.](fgene-11-00074-g001){#f1}

![Rare variants of BB genotypes on four cystine urolithiasis (CU) families. Solid squares or circles mean the patients were affected by CU. Open squares or circles denote that the patients were not affected by CU.](fgene-11-00074-g002){#f2}

![Rare variants of AB, A or B genotypes in three cystine urolithiasis (CU) families. Solid squares or circles mean the patients were affected by CU. Open squares or circles denote that the patients were not affected by CU.](fgene-11-00074-g003){#f3}

Among these 24 variants, 15 have not been reported elsewhere (9 on *SLC3A1*, 6 on *SLC7A9*).

According to the ACMG/AMP 2015 guideline classification ([**Table 2**](#T2){ref-type="table"}), five of the nine *SLC3A1* variants were pathogenic and four were likely pathogenic; two of the six *SLC7A9* variants were pathogenic and another two were likely pathogenic. The classifications of the remaining two variants of *SLC7A9* were uncertain. These 15 novel variants included the following: (1) For *SLC3A1*: c.2011C \> T:p.Arg671Ter, c.1326C \> G:p.Asn442Lys, c.1304T \> G:p.Met435Arg, c.1113C \> A:p.Tyr371Ter, c.1365delG:p.Ser455Valfs, c.817T \> C:p.Cys273Arg, c.1097A \> G:p.Gln366Arg, c.1332+2T \> A, and c.2011C \> T:p.Arg671Ter. (2)For *SLC7A9*: c.525delC:p.Tyr175Ter, c.1399+5C \> G,c.538_540del:p.180_180del, c.236G \> T:p.Gly79Val, c.767T \> C:p.Ile256Thr, and exon11:c.1201A \> T:p.Lys401Ter.

Further functional effects were tested for all variants *via* three programs in silico (i.e., REVEL, ClinPred, and MutationTaster). Results showed that 13 of the 15 novel variants were damaging, disease-causing, or pathogenic ([**Table 3**](#T3){ref-type="table"}).

###### 

Effect predictions of rare variants by three in silico software. REVEL: V0.21.0 (<http://revel.github.io/>); ClinPred ([@B1]); MutationTaster ([@B15]).

  Gene     Variant                           Effect          REVEL      ClinPred     MutationTaster
  -------- --------------------------------- --------------- ---------- ------------ -----------------
  SLC3A1   exon6:c.1084C \> T:p.Arg362Cys    nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC3A1   exon10:c.2011C \> T:p.Arg671Ter   stopgain        --                      Disease_causing
  SLC3A1   exon7:c.1326C \> G:p.Asn442Lys    nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC3A1   exon10:c.1640C \> T:p.Ser547Leu   nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC7A9   exon5:c.525delC:p.Tyr175Ter       stopgain        --                      Disease_causing
  SLC7A9   Intron12:c.1399+5C \> G           --              --                      --
  SLC3A1   exon7:c.1304T \> G:p.Met435Arg    nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC3A1   exon8:c.1414C \> T:p.Leu472Phe    nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC3A1   exon6:c.1113C \> A:p.Tyr371Ter    stopgain        --                      Disease_causing
  SLC3A1   exon8:c.1365delG:p.Ser455fs       frameshift      --                      Disease_causing
  SLC3A1   exon6:c.1084C \> G:p.Arg362Gly    nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC7A9   c.538_540del:p.Phe180del          --              --                      --
  SLC7A9   exon4:c.236G \> T:p.Gly79Val      nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC7A9   exon8:c.767T \> C:p.Ile256Thr     nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC7A9   exon4:c.236G \> T:p.Gly79Val      nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC7A9   exon8:c.767T \> C:p.Ile256Thr     nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC3A1   exon4:c.817T \> C:p.Cys273Arg     nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC3A1   exon6:c.1097A \> G:p.Gln366Arg    nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC3A1   exon5:c.1012-1G \> A              splicing        --         --           Disease_causing
  SLC7A9   intron12:c.1399+2_3insT           splicing        --                      Disease_causing
  SLC7A9   exon3:c.151T \> C:p.Ser51Pro      nonsynonymous   Damaging   pathogenic   Disease_causing
  SLC7A9   exon11:c.1201A \> T:p.Lys401Ter   stopgain        --         --           Disease_causing
  SLC3A1   Intron7:c.1332+2T \> A            splicing        --                      Disease_causing
  SLC3A1   exon10:c.2011C \> T:p.Arg671Ter   stopgain        --                      Disease_causing

The remaining two *SLC7A9* variants (i.e., c.1399+5C \> G and c.538_540del:p.Phe180del) were likely pathogenic. Thus, further confirmatory experiments are needed.

Genotype-Phenotype Correlation for 13 CU Families {#s3_3}
-------------------------------------------------

The 13 CU families were divided into three groups: classical AR inheritance (six AA and four BB genotypes), AD inheritance (one A and one B genotype), and digenic inheritance (one AB genotype) ([**Table 4**](#T4){ref-type="table"}). Several points were observed in this study: (1) *SLC3A1* is the main disease gene for childhood CU. *SLC3A1* is mutated in 8 out of the 13 patients with CU and the number of stones is 2--9 for AA genotype and 1--3 for BB genotype. (2) Patients with AD inheritance had the highest number of stones. In family number 10 with A genotype, the number of stones is 14. In family number 11 with B genotype, the number of stones is 9. (3) Childhood CU may represent a more aggressive form. By contrast, the pathogenic variants in *SLC3A1* or *SLC7A9* ([@B6]) cannot all be detected in cystiruia patients. In this study, we detected the pathogenic variants in *SLC3A1* or *SLC7A9* in all CU patients, suggesting that pediatric CU patients may represent a more aggressive group.

###### 

In-brief lists of genotype and phenotype data for 13 families with cystine urolithiasis.

  Inheritance   Genotype   Number of patients   Onset age   Stone size   Stone number
  ------------- ---------- -------------------- ----------- ------------ --------------
  AR            AA         6                    1-9.3       1.18-7.75    2-9
  BB            4          1.5-8.3              0.26-7.77   1-3          
  AD            A          1                    2.9         18.67        14
  B             1          0.6                  1.17        9            
  Digenic       AB         1                    2.8         3.41         2

AD, autosomal dominant; AR, autosomal recessive; Onset age: Years; Stone size: cm^3^.

Phenotypic Details for Three CU Patients With Heterozygous Variants {#s3_4}
-------------------------------------------------------------------

Three cases harboring *SLC3A1* or (and) *SLC7A9* heterozygous variants were identified. For patient number 6 with AB genotype, no clinical symptom of urolithiasis was observed during health examinations. The patient\'s 24-h urinary calcium was 0.42 mmol/L, 24-h urinary phosphorus was 9.75 mmol/L, serum calcium was 2.38 mmol/L, serum phosphate was 1.61 mmol/L, BUN was 3.39 mmol/L, CREA was 18.32 µmol/L, and UA was 269.31 µmol/L. However, the B ultrasound detected stones in the patient\'s urinary system.

Patient number 10 with A genotype carried an *SLC3A1* spicing variant (c.1012-1G \> A) that was previously reported as pathogenic ([@B13]). The patient\'s initial symptom was dysuria but without urinary frequency and urgency. His 24-h urinary calcium was 0.12 mmol/L, 24-h urinary phosphorus was 7.94 mmol/L, serum calcium was 2.24 mmol/L, BUN was 4.42 mmol/L, CREA was 41.65 µmol/L, and serum UA was 182.91 µmol/L.

Patient number 11 with B genotype carried an *SLC7A9* spicing variant (1399 + 2_3insT) that was also previously reported as pathogenic ([@B19]). The patient had spontaneous discharge of small stones (at 3 months old) according to his parents. The patient\'s 24-h urinary calcium was 0.59 mmol/L, 24-h urinary phosphorus was 3.92 mmol/L, serum calcium was 2.24 mmol/L, serum phosphate was 2.19 mmol/L, BUN was 3.37 mmol/L, CREA was 32.2 µmol/L, and serum-UA was 217.26 µmol/L.

Discussion {#s4}
==========

Cystinuria is a metabolic disease caused by defects in the *SLC3A1* and *SLC7A9* genes. These gene defects result in decreased renal reabsorption of cystine, ornithine, arginine, and lysine. Most patients with cystinuria develop CU, but the age at onset varies ([@B10]). In this study, we subjected 13 patients with pediatric CU to mutation screening and observed typical *SLC3A1* and *SLC7A9* pathogenic variants consistent with AA, BB, or AB genotypes in 11 of the families with CU and heterozygous *SLC3A1* and *SLC7A9* rare variants in two of the families with CU (i.e., family numbers 10 and 11). Family numbers 10 and 11 suffer from c.1012-1G \> A and 1399 + 2_3insT splicing variants, respectively. These two variants were reported previously as pathogenic ([@B9]; [@B10]). However, no CU phenotypes were observed for both maternal carriers. This situation may be indicative of the non-full penetrance for the heterozygous mutation in females.

According to the ACMG/AMP 2015 guidelines or the predictions by the software in silico, all 24 rare variants are pathogenic, likely pathogenic, disease-causing, or damaging ([**Tables 2**](#T2){ref-type="table"} and [**3**](#T3){ref-type="table"}). This result is similar to that obtained by another study ([@B17]). [@B17] examined 13 pediatric patients with CU and found that all patients harbored pathogenic *SLC3A1* or *SLC7A9* variants. These results raise the question of whether newborns with mutations in the *SLAC3A1* or *SLC7A9* genes should be afforded certain precautions, especially as next-generation sequencing has become widely available.

As a global disorder, the prevalence of cystinuria varies in different populations, and hotspot mutations have been described previously. The typical mutation hotspot site is *SLC3A1* p.Met467Thr ([@B18]; [@B9]; [@B2]; [@B6]). A study reported that 0.5% of the Swedish population carries the hotspot variant ([@B9]). China is the most populated country in the world. However, to the best of our knowledge, only four studies (including the present study) have been conducted in China concerning this topic. These studies involved 40 patients in total ([@B19]; [@B17]; [@B11]). A total of 26 *SLC3A1* and 21 *SLC7A9* pathogenic variants have been reported in the Chinese population. As shown in [**Figure 4**](#f4){ref-type="fig"}, the Chinese variants were evenly distributed through the *SLC3A1* or *SLC7A9* genes, and only five *SLC3A1* and six *SLC7A9* variants were reported twice. No *SLC3A1*-p.Met467Thr was detected in the Chinese patients ([**Figure 4**](#f4){ref-type="fig"}). Therefore, the *SLC3A1* and *SLC7A9* variants in the patients likely represent mutation spectra that differ from those in other populations.

![Schematic presentation of *SLC3A1* or *SLC7A9* pathogenic variants in the Chinese population that have been reported thus far. One dot (at the end of the variants) represents the variants reported by [@B19]. Two dots denote the variants reported by [@B17]. Three dots mean the variants reported by [@B11]. Red dots are the variants identified in the present study.](fgene-11-00074-g004){#f4}

Conclusions {#s5}
===========

We detected a total of 24 rare variants in the *SCL3A1* and *SLC7A9* genes from 13 families with CU. Among these variants, 15 were novel. Functional evaluation analysis confirmed that all these novel variants are pathogenic, damaging, or disease-causing. These data expanded the spectrum of CU variants in the Chinese population.
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